Phase 2 Trial of Zanzalintinib and Pembrolizumab in Select Subtypes of Advanced/Metastatic Soft-tissue Sarcoma

Part of paid clinical trials in Houston, Texas.

Sponsor
M.D. Anderson Cancer Center
Study ID
NCT07283731
Phase
PHASE2
Status
Recruiting
Apply to this trial

Conditions

  • Advanced/Metastatic
  • Pembrolizumab
  • Phase 2
  • Soft-Tissue Sarcoma
  • Zanzalintinib

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Zanzalintinib — DRUG
    Given by po
  • Pembrolizumab — DRUG
    Given by iv

Study Details

To learn if zanzalintinib and pembrolizumab can help to control select subtypes of advanced/metastatic soft-tissue sarcoma (UPS, MFS, HGPS, and HGUS

Key Dates

Start date
Jun 2, 2026
Status verified
Apr 2026
Primary completion
Nov 1, 2028
Completion
Nov 1, 2030

Study Design

Enrollment
20 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Single Arm
    Treatment with Zanzalintinib + Pembrolizumab

Primary Outcome Measure

Safety and adverse events (AEs) [ Time Frame: Through study completion; an average of 1 year ]

Central Contacts

Locations (1)

FacilityCityStateZIPSite coordinators
MD Anderson Cancer CenterHoustonTexas77030
Michael S Nakazawa, MD
[email protected]
713-410-3409
Michael S Nakazawa, MD (SUB_INVESTIGATOR)

Find similar trials in Houston, TX

By research site
MD Anderson Cancer Center· Houston, TX

Related Studies